Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia (FluCOP Trial)

NCT05216614 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT05216614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05216614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia (FluCOP Trial)
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Withdrawn
Start date
December 14, 2021
Completion date
February 22, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, olfactory disorder, parosmia